PMID- 20566415
OWN - NLM
STAT- MEDLINE
DCOM- 20110131
LR  - 20220316
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 641
IP  - 2-3
DP  - 2010 Sep 1
TI  - Antiproliferation of cardamonin is involved in mTOR on aortic smooth muscle cells 
      in high fructose-induced insulin resistance rats.
PG  - 179-86
LID - 10.1016/j.ejphar.2010.05.024 [doi]
AB  - The objective of this study was to determine possible effects and potential 
      mechanisms of cardamonin on improving insulin resistance and vascular 
      proliferative lesions in the rat's model system. Fed with 60% fructose-enriched 
      diet for 12 weeks, male Sprague-Dawley (SD) rats developed insulin resistance and 
      hyperinsulinemia. They also showed excessive proliferation of the vascular smooth 
      muscle cells (VSMCs) and activation of the mammalian target of rapamycin 
      (mTOR)/translation control proteins p70 ribosomal S6 kinase (P70S6K1)/eukaryotic 
      initiation factor 4E binding protein 1 (4E-BP1) signaling in the rat thoracic 
      aorta. From weeks 9-12, cardamonin was injected into the peritoneal cavity once 
      daily. Under the detection of microscopy and electron microscopy, cardamonin 
      improved hyperinsulinemia and inhibited proliferation of VSMCs in the thoracic 
      aorta of rats in a dose-dependent manner. By the Real-Time RT-PCR, mRNA 
      expression of mTOR, P70S6K1 and 4E-BP1 was significantly reduced in cardamonin 
      treated rats. Similarly, protein over-expression of mTOR and p-P70S6K1 was 
      obviously inhibited by immunohistochemical analyses. These findings suggest that 
      cardamonin may play a role in ameliorating insulin resistance and smooth muscle 
      hyperplasia of major vessels in fructose-induced rats, possibly via a mechanism 
      that involves the modulation of insulin/mTOR signaling.
CI  - Copyright (c) 2010 Elsevier B.V. All rights reserved.
FAU - Liao, Qin
AU  - Liao Q
AD  - Department of Pharmacy, Fuzhou General Hospital of Nanjing Military Command, 
      Fujian Fuzhou, China.
FAU - Shi, Dao-Hua
AU  - Shi DH
FAU - Zheng, Wei
AU  - Zheng W
FAU - Xu, Xiang-Jin
AU  - Xu XJ
FAU - Yu, Ying-Hao
AU  - Yu YH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100604
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Carrier Proteins)
RN  - 0 (Chalcones)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 30237-26-4 (Fructose)
RN  - EC 2.7.1.1 (mTOR protein, rat)
RN  - EC 2.7.11.1 (Ribosomal Protein S6 Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - H8KP1OJ8JX (cardamonin)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Aorta, Thoracic/cytology/metabolism/ultrastructure
MH  - Carrier Proteins/metabolism
MH  - Cell Proliferation/*drug effects
MH  - Chalcones/chemistry/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Fructose/*pharmacology
MH  - Hyperinsulinism/drug therapy
MH  - Hypoglycemic Agents/pharmacology
MH  - Insulin/metabolism/pharmacology
MH  - Insulin Resistance/*physiology
MH  - Male
MH  - Mammals
MH  - Molecular Structure
MH  - Muscle, Smooth, Vascular/pathology/ultrastructure
MH  - Myocytes, Smooth Muscle/*metabolism
MH  - Random Allocation
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Ribosomal Protein S6 Kinases/metabolism
MH  - Signal Transduction/drug effects/physiology
MH  - Sirolimus/pharmacology
MH  - TOR Serine-Threonine Kinases/*metabolism
EDAT- 2010/06/23 06:00
MHDA- 2011/02/01 06:00
CRDT- 2010/06/23 06:00
PHST- 2009/09/07 00:00 [received]
PHST- 2010/04/17 00:00 [revised]
PHST- 2010/05/23 00:00 [accepted]
PHST- 2010/06/23 06:00 [entrez]
PHST- 2010/06/23 06:00 [pubmed]
PHST- 2011/02/01 06:00 [medline]
AID - S0014-2999(10)00474-7 [pii]
AID - 10.1016/j.ejphar.2010.05.024 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2010 Sep 1;641(2-3):179-86. doi: 10.1016/j.ejphar.2010.05.024. 
      Epub 2010 Jun 4.